ProCE Banner Activity

How I Am Using CDK4/6 Inhibitors for My Patients With Hormone Receptor–Positive MBC

Clinical Thought
Are you considering CDK4/6 inhibitors as part of your treatment armamentarium for patients with hormone receptor–positive metastatic breast cancer? Dr. Jahanzeb provides insights from his experience.

Released: September 21, 2016

Expiration: September 20, 2017

No longer available for credit.

Share

Faculty

Mohammad Jahanzeb

Mohammad Jahanzeb, MD, FACP

Professor of Clinical Medicine, Hematology-Oncology 
Medical Director, UM Sylvester Deerfield Campus
Associate Center Director for Community Outreach
Sylvester Comprehensive Cancer Center
University of Miami, Miller School of Medicine
Deerfield Beach, Miami

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by an educational grant from

Genentech Roche Virology

Partners

LBBC

ProCE Banner

Faculty Disclosure

Primary Author

Mohammad Jahanzeb, MD, FACP

Professor of Clinical Medicine, Hematology-Oncology 
Medical Director, UM Sylvester Deerfield Campus
Associate Center Director for Community Outreach
Sylvester Comprehensive Cancer Center
University of Miami, Miller School of Medicine
Deerfield Beach, Miami

Mohammad Jahanzeb, MD, FACP, has disclosed that he has received consulting fees from Genentech and Novartis and funds for research support from AbbVie, Genentech, and Lilly.